Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Journal of Medicinal Chemistry
|
January 2, 2010
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation
Zhaoning Zhu, Zhong-Yue Sun, Yuanzan Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J Fell, Christian Mirescu, Kallol Basu, et al.
Journal of Medicinal Chemistry
|
November 3, 2018
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety
Mihirbaran Mandal, Kaushik Mitra, Diane Grotz, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2012
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor
Jared N Cumming, Elizabeth M Smith, Lingyan Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 13, 2014
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition
Justyna A Dobrowolska, Maria S Michener, Guoxin Wu, et al.
Journal of Medicinal Chemistry
|
September 20, 2012
Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation
Mihirbaran Mandal, Zhaoning Zhu, Jared N Cumming, et al.
Science Translational Medicine
|
November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2013
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction
Andrew W Stamford, Jack D Scott, Sarah W Li, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease
Jack D Scott, Sarah W Li, Andrew P J Brunskill, et al.
Nature Medicine
|
June 24, 2020
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease
Simon Dujardin, Caitlin Commins, Aurelien Lathuiliere, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Journal of Medicinal Chemistry
|
January 2, 2010
Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation
Zhaoning Zhu, Zhong-Yue Sun, Yuanzan Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 27, 2015
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J Fell, Christian Mirescu, Kallol Basu, et al.
Journal of Medicinal Chemistry
|
November 3, 2018
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety
Mihirbaran Mandal, Kaushik Mitra, Diane Grotz, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 7, 2012
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor
Jared N Cumming, Elizabeth M Smith, Lingyan Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
June 13, 2014
CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition
Justyna A Dobrowolska, Maria S Michener, Guoxin Wu, et al.
Journal of Medicinal Chemistry
|
September 20, 2012
Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation
Mihirbaran Mandal, Zhaoning Zhu, Jared N Cumming, et al.
Science Translational Medicine
|
November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Matthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
ACS Medicinal Chemistry Letters
|
February 16, 2013
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction
Andrew W Stamford, Jack D Scott, Sarah W Li, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease
Jack D Scott, Sarah W Li, Andrew P J Brunskill, et al.
Nature Medicine
|
June 24, 2020
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease
Simon Dujardin, Caitlin Commins, Aurelien Lathuiliere, et al.
Page
of 4